
Moderna (MRNA) Stock
Healthcare sector company. Here's the price, business snapshot, and what's worth knowing about Moderna in November 2026.
Moderna, Inc. (MRNA) is a biotechnology company centred on messenger RNA (mRNA) technology, best known for its COVID‑19 vaccine. The company applies its platform to develop vaccines and therapeutics across infectious diseases (influenza, RSV, CMV) and oncology, aiming for faster design and scalable manufacturing. Investors should know Moderna’s prospects combine platform-driven upside with typical biotech risks: revenues can be lumpy, clinical trials are binary events, and regulatory approvals and competition (notably Pfizer/BioNTech) materially affect the outlook. The market capitalisation reflects the transition from pandemic-era demand to a broader commercial strategy. Moderna invests heavily in R&D and capacity, which can pressure margins in the near term but may support future growth if programmes succeed. This stock tends to be higher volatility and may suit investors with a longer timeframe and higher risk tolerance. This is general information, not personalised investment advice.
Moderna (MRNA) Stock Forecast
Analyst price target, next 12 months
$127.25
-41.2% vs today's $216.57
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Moderna have a consensus 12-month target of $127.25, below the current price of $216.57.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 18 Nov 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Six-Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Moderna's stock, expecting it to be worth $124.33 in the future.
Financial Health
Moderna is generating strong revenue and cash flow, indicating a solid financial position.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring MRNA
HIV Therapeutics (Once-Daily Pill) Reshapes Market
Gilead Sciences has secured FDA approval for a new once-daily HIV combination pill, streamlining therapy for millions of suppressed patients. This regulatory milestone spotlights investment opportunities in pioneering biopharmaceutical companies and drug delivery developers focused on advanced antiviral treatments.
Published: 28 August 2026
Explore BasketmRNA Vaccines: Could Non-COVID Markets Drive Growth?
The FDA has granted its first-ever approval for an mRNA seasonal flu vaccine, moving the groundbreaking technology beyond its pandemic origins. This regulatory milestone creates compelling investment opportunities across innovative biotechnology firms and the specialized supply chains that support them.
Published: 7 August 2026
Explore BasketLNP Patent Holders Shape Drug Delivery Value 2025
The massive settlement between Moderna and Arbutus/Genevant highlights the critical value of the lipid nanoparticle (LNP) technology used in mRNA vaccines. This creates a potential investment opportunity in companies that hold key patents for drug delivery systems, as they may be poised for lucrative licensing deals or acquisitions.
Published: 4 March 2026
Explore BasketBiotech Patent Dispute Explained (BioNTech vs Moderna)
BioNTech is suing Moderna for patent infringement over its next-gen COVID-19 vaccine, escalating the legal rivalry between the two biotech leaders. This dispute creates a potential opening for other vaccine developers to gain a competitive edge while the giants are locked in a legal battle.
Published: 20 February 2026
Explore BasketInvestment Opportunities in RNA Therapeutics Explained
Eli Lilly's $2.4 billion acquisition of Orna Therapeutics signals a major bet on circular RNA and in vivo cell engineering. This theme focuses on the broader ecosystem of companies developing the next-generation platforms and delivery technologies essential for advancing genetic medicine.
Published: 10 February 2026
Explore BasketCancer Therapies: What's Next After 100% Response Rate
Regeneron's announcement of a 100% response rate for its new lymphoma therapy highlights a major advancement in cancer treatment. This breakthrough creates an investment opportunity centered on companies pioneering next-generation immuno-oncology drugs, particularly those developing bispecific antibodies and other innovative platforms.
Published: 7 December 2025
Explore BasketBeyond Vaccines: The mRNA Revolution
BioNTech's strong vaccine sales are fueling its expansion into new medical fields, particularly cancer treatment. This strategic shift highlights a broader investment opportunity in companies pioneering the next wave of mRNA-based therapies.
Published: 5 August 2025
Explore BasketHypertension Therapy Innovators
This carefully selected group of stocks represents companies at the forefront of developing breakthrough treatments for hypertension, a condition affecting over a billion people worldwide. Following AstraZeneca's groundbreaking trial results, these pharmaceutical innovators are positioned to potentially transform cardiovascular medicine and address a massive unmet medical need.
Published: 15 July 2025
Explore BasketPediatric Vaccine Rollout
This carefully selected group of stocks represents companies positioned to benefit from the full FDA approval of COVID-19 vaccines for at-risk children. Our professional analysts have identified opportunities across the entire value chain, from vaccine manufacturers to healthcare providers and clinical research organizations.
Published: 11 July 2025
Explore BasketWhy You’ll Want to Watch This Stock
Platform-driven growth
Moderna’s mRNA platform can speed development and scale production, offering potential for new products — though trial outcomes and approvals remain uncertain.
Pipeline diversification
Programmes in flu, RSV, CMV and oncology could broaden revenue streams, but each faces clinical and regulatory hurdles that create binary outcomes.
Commercial dynamics
Post‑pandemic demand, pricing and competition shape future sales; market conditions can change quickly and past performance is no guarantee of future results.
Compare Moderna with other stocks


Pfizer vs Moderna
Pfizer vs Moderna: A Stock Comparison
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.